DYADIC INTERNATIONAL INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- DYADIC INTERNATIONAL INC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- DYADIC INTERNATIONAL INC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares.
- DYADIC INTERNATIONAL INC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- DYADIC INTERNATIONAL INC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-03-31 was 55.00K shares.
- DYADIC INTERNATIONAL INC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 55.00K shares, a 0.00% change from fiscal 2024.
- DYADIC INTERNATIONAL INC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 55.00K shares.
- DYADIC INTERNATIONAL INC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares, a 100.00% decline from fiscal 2022.
- DYADIC INTERNATIONAL INC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 333.94K shares, a 54.57% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | 55.00K shares 10-K · filed 2026-03-25 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 104.43K shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 104.43K shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2025-03-31 | 55.00K shares 10-Q · filed 2025-05-14 | 110.00K shares derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-12-31 | 49.43K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | 55.00K shares 10-K · filed 2026-03-25 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 5.57K shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | 5.57K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 5.57K shares derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-14 | 0.00 shares derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | 0.00 shares 10-K · filed 2025-03-26 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 100.00K shares derived: sum of 4 quarters · filed 2024-03-28 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 298.94K shares derived: sum of 4 quarters · filed 2024-03-28 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-10 | 298.94K shares derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-12-31 | 100.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 333.94K shares 10-K · filed 2024-03-28 |
| 2022-09-30 | 198.94K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 383.94K shares derived: sum of 4 quarters · filed 2023-03-29 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | 185.00K shares derived: sum of 4 quarters · filed 2023-03-29 |
| 2022-03-31 | 35.00K shares 10-Q · filed 2022-05-12 | 710.00K shares derived: sum of 4 quarters · filed 2023-03-29 |
| 2021-12-31 | 150.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | 735.00K shares 10-K · filed 2023-03-29 |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 597.00K shares derived: sum of 4 quarters · filed 2022-03-29 |
| 2021-06-30 | 525.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 597.00K shares derived: sum of 4 quarters · filed 2022-03-29 |
| 2021-03-31 | 60.00K shares 10-Q · filed 2021-05-13 | 85.00K shares derived: sum of 4 quarters · filed 2022-03-29 |
| 2020-12-31 | 12.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | 135.00K shares 10-K · filed 2022-03-29 |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | 269.00K shares derived: sum of 4 quarters · filed 2021-03-30 |
| 2020-06-30 | 13.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | 371.00K shares derived: sum of 4 quarters · filed 2021-03-30 |
| 2020-03-31 | 110.00K shares 10-Q · filed 2020-05-14 | 891.50K shares derived: sum of 4 quarters · filed 2021-03-30 |
| 2019-12-31 | 146.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | 781.50K shares 10-K · filed 2021-03-30 |
| 2019-09-30 | 102.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | |
| 2019-06-30 | 533.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | |
| 2019-03-31 | 0.00 shares 10-Q · filed 2019-05-09 | |
| 2018-12-31 | 30.00K shares 10-K · filed 2020-03-30 | |
| 2017-12-31 | 6.25K shares 10-K · filed 2019-03-27 | |
| 2016-12-31 | 6.25K shares 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |